What are the precautions for using Koselugo

Koselugo is an anti-cancer drug targeting MEK protein, which inhibits tumor cell proliferation by blocking cell signaling and has significant efficacy in specific cancer types.

What are the precautions for using Koselugo

There are two special points to pay attention to when using Koselugo:

1. Cardiomyopathy

For patients with cardiomyopathy, particularly those with impaired LVEF, ejection fraction should be assessed prior to treatment, monitored regularly during treatment, and medication adjusted according to cardiac function;

2. Ocular toxicity

In view of the risk of ocular toxicity, a comprehensive ophthalmologic evaluation is required before, after, and during treatment, and when visual abnormalities or ocular toxicity occur, it is necessary to immediately evaluate and adjust the medication strategy as appropriate to ensure patient safety.

When understanding the therapeutic effect of Koselugo, we also need to pay attention to the precautions during its use to ensure that it is safe and effective; In particular, for patients with cardiomyopathy, the possible adverse reactions caused by Koselugo are the focus of close attention.

Adverse effects of Koselugo in patients with cardiomyopathy

When Koselugo is used in patients with cardiomyopathy, two adverse effects may occur:

1. Impaired cardiac function

Further impairment of cardiac function, manifested by a significant decrease in left ventricular ejection fraction (LVEF), may lead to heart failure symptoms such as dyspnea, edema, etc.;

2. Arrhythmias

Arrhythmias, including bradycardia, tachycardia, or conduction block, can increase the risk of cardiac arrest.

Patients with cardiomyopathy need to be fully evaluated before Koselugo is used, and cardiac function should be closely monitored during treatment.

Patients with cardiomyopathy should be alert to possible adverse effects when using Koselugo, which may increase the burden on the heart; At the same time, Koselugo may also cause ocular toxicity, and its clinical manifestations are diverse, which needs to be paid enough attention.

Clinical manifestations of ocular toxicity with Koselugo

There are two main clinical manifestations of ocular toxicity that Koselugo may cause:

1. Retinal vein occlusion (RVO)

Patients may have symptoms such as blurred vision, visual field defects, dark shadows in front of the eyes, and in severe cases, blindness;

2. Retinal pigment epithelium detachment (RPED)

Patients may present with floating dark shadows or scotomas in the visual field, which may be accompanied by decreased visual acuity as the disease progresses. As soon as these ocular symptoms develop, seek immediate medical attention and consider adjusting the treatment regimen for Koselugo.

【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.